Top-notch biotech stock Pharvaris surged Monday after the FDA said it could begin testing a treatment for a swelling disorder in people.

The post Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision appeared first on Investor’s Business Daily.